Collaborative Atorvastatin Diabetes Study (CARDS).ppt

下载文档

3
0
约5.16千字
约 8页
2017-08-07 发布于甘肃
举报
版权申诉
保障服务

Collaborative Atorvastatin Diabetes Study (CARDS).ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

0115010821 Ballantyne MD Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women 40–75 years of age Primary CHD and stroke prevention LDL-C ?160 mg/dL (?4.14 mmol/L) TG ?600 mg/dL (?6.78 mmol/L) ?1 additional RF HTN (or on HTN treatment) Retinopathy Albuminuria Current smoking CARDS: Patient Baseline Characteristics CARDS: Patient Baseline Lipids CARDS: Effect of Atorvastatin on the Primary Endpoint: Major CV Events Including Stroke CARDS: Adverse and Serious Adverse Events Primary Prevention Trials of Lipid-Altering Therapy Including Patients with Diabetes Secondary Prevention Trials of Lipid-Altering Therapy Including Patients with Diabetes Slide Source: Lipids Online Slide Library Colhoun HM et al. Lancet 2004;364:685-696. Patient Population Primary endpoint: time to first major CV event (CHD death, nonfatal MI, unstable angina, resuscitated cardiac arrest, coronary revascularization, stroke Secondary endpoints: total mortality, any CV endpoint, lipids, and lipoproteins 2838 patients 4-year follow-up Atorvastatin 10 mg (n=1428) Double-blind placebo (n=1410) BMI 1350 (95%) 1326 (94%) White ethnicity 703 (49%) 708 (50%) 60–70 558 (39%) 529 (38%) 60 61.5 (8.3) 61.8 (8.0) Mean (SD) years Age 515 (36%) 28.7 (3.6) 456 (32%) 167 (12%) Atorvastatin(n = 1428) 538 (38%) Obese (BMI 30 kg/m2) 28.8 (3.5) Mean (SD), kg/m2 453 (32%) Women 173 (12%) 70 Placebo(n = 1410) Colhoun HM et al. Lancet 2004;364:685-696. Reprinted with permission from Elsevier. 54 (12)1.39 (0.32) 55 (13)1.42 (0.34) HDL cholesterol (mg/dL)(mmol/L) 118 (28)3.04 (0.72) 117 (27)3.02 (0.70) LDL cholesterol (mg/dL)(mmol/L) 207 (32)5.36 (0.83) 207 (32)5.35 (0.82) Total cholesterol (mg/dL)(mmol/L) 150 (106–212)1.70 (1.20–2.40) Atorvastatin(n = 1428)Mean (SD) 148 (104–212)1.67 (1.17–2.40) Triglycerides* (mg/dL)(mmol/L) Placebo(n = 1410)Mean (SD) *Median (interquartile range) Colhoun HM et al. Lancet 2004;364:685-696. Reprinted with permis